Epidermal growth factor receptor serum levels and prognostic value in malignant gliomas

Tumori

Volumn 93, Issue 3, 2007, Pages 275-280

  Quaranta, Michele ^a   Divella, Rosa ^a   Daniele, Antonella ^a   Di Tardo, Silvia ^a   Venneri, Maria Teresa ^a   Lolli, Ivan ^b   Troccoli, Giuseppe ^b  

^a NATIONAL CANCER INSTITUTE GIOVANNI PAOLO II   (Italy)

^b UNIVERSITY OF BARI   (Italy)

Author keywords

Anaplastic astrocytoma; Epidermal growth factor receptor; Glioblastoma multiforme

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; TEMOZOLOMIDE;

ADULT; AGED; ARTICLE; BLOOD LEVEL; CANCER GROWTH; CANCER SURVIVAL; CELL DIVISION; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FOLLOW UP; GLIOBLASTOMA; HUMAN; MAJOR CLINICAL STUDY; MALE; PROGNOSIS; STEREOTAXIC SURGERY;

EID: 34447572690     PISSN: 03008916     EISSN: None     Source Type: Journal    
DOI: 10.1177/030089160709300308     Document Type: Article

References (32)

1. Olayioye MA, Neve RM, Lane HA: The ErbB signalling network: receptor heterodimerization in development and cancer. EMBO J, 19: 3159-3167, 2000.
2. Thomas CY, Chouinard M, Cox M, Parsons S, Stallings-Mann M, Garcia R, Jove R, Wharen R: Spontaneous activation and signalling by overexpressed epidermal growth factor receptors in glioblastoma cells. Int J Cancer, 10: 19-27, 2003.
3. Wells A: EGF receptor. Int J Biochem Cell Biol, 31: 637-643, 1999.
4. Zawrocki A, Biernat W: Epidermal growth factor receptor in glioblastoma. Folia Neuropathol, 43: 123-32, 2005.
5. Hui AB, Lo KW, Yin XL, Poon WS, Ng HK: Detection of multiple gene amplifications in glioblastoma multiforme using array-based comparative genomic hybridization. Lab Invest, 81: 717-23, 2001.
6. Barker FG 2nd, Simmons ML, Chang SM: EGFR overexpression and radiation response in glioblastoma multiforme. Int J Radiat Oncol Biol Phys, 51: 410-418, 2001.
7. Arslantas A, Artan S, Oner U, Muslumanoglu H, Durmaz R, Cosan E, Atasoy MA, Basaran N, Tel E: The importance of genomic copy number changes in the prognosis of glioblastoma multiforme. Neurosurg Rev. 27: 58-64, 2004.
8. Aldape KD, Ballman K, Furth A, Buckner JC, Giannini C, Burger PC, Scheithauer BW, Jenkis RB, James CD: Immunohistochemical detection of EGFRvIII in high malignancy grade astrocytomas and evaluation of prognostic significance. J Neuropathol Exp Neurol, 63: 700-707, 2004.
9. Bouvier-Labit C, Chinot O, Ochi C, Gambarelli D, Dufour H, Figarella-Branger D: Prognostic significance of ki67, p53 and epidermal growth factor receptor immunostainig in human glioblastomas. Neuropatholog Appl Neurobiol, 24: 381-388,1998.
10. Choi JH, Oh JY, Ryu SK, Kim SJ, Lee NY, Kim YS, Yi SY, Shim KS, Han WS: Detection of epidermal growth factor receptor in the serum of gastric carcinoma patients. Cancer, 79: 1879-1883, 1997.
11. Partanen R, Hemminki K, Koskinen H, Luo JC, Careny WP, Brandt-Raup PW: The detection of increased amounts of the extracellular domain of the epidermal growth factor receptor in serum during carcinogenesis in asbestosis patients. J Occup Med, 36: 1324, 1994.
12. Oh MJ, Choi JH, Hokim I, Lee YH, Huh JY: Detection of epidermal growth factor receptor in the serum of patients with cervical carcinoma. Clin Cancer Res, 6: 4760-4763, 2000.
13. Bruce EJ, Pasi AJ: Epidermal growth factor receptor mutations in patients with non-small cell lung cancer. Cancer Res, 65: 7525-7529, 2005.
14. Mitsuhashi A, Tanaka N, Suzuka K, Matsui H, Seki K, Sekiya S: Detection of epidermal growth factor receptor mRNA in peripheral blood of cervical cancer patients. Gynecol Oncol, 89: 480-485, 2003.
15. Gazzanica P, Gandini O, Giuliani L, Magnanti M, Gradilone A, Silvestri I: Detection of epidermal growth factor receptor mRNA in peripheral blood: a new marker of circulating neoplastic cells in bladder cancer patients. Clin Cancer Res, 7: 577-583, 2001.
16. Hulleman E, Helin K: Molecular mechanisms in gliomagenesis. Adv Cancer Res, 94: 1-27, 2005.
17. Furuta M, Weil RJ, Vortmeyer AO, Huang S, Lei J, Huang TN, Lee YS, Bhowmick DA, Lubensky IA, Oldfield EH, Zhuang Z: Protein patterns and proteins that identify subtypes of glioblastoma multiforme. Oncogene, 23: 6806-6814, 2004.
18. Jaros E, Perry RH, Adam L, Kelly PJ, Crawford PJ, Kalbag RM, Mendelow AD, Sengupta RP, Pearson AD: Prognostic implications of p53 protein, epidermal growth factor receptor, and Ki-67 labelling in brain tumours. Br J Cancer, 66: 373-385, 1992.
19. Kitange GJ, Smith JS, Jenkins RB: Genetic alterations and chemotherapeutic response in human diffuse gliomas. Expert Rev Anticancer Ther, 1: 595-605, 2001.
20. Newcomb EW, Cohen H, Lee SR, Bhalla SK, Bloom J, Hayes RL, Miller DC: Survival of patients with glioblastoma multiforme is not influenced by altered expression of p16, p53, EGFR, MDM2 or Bcl-2 genes. Brain Pathol, 8: 655-667, 1998.
21. Huncharek M, Kupelnick B: Epidermal growth factor receptor gene amplification as a prognostic marker in glioblastoma multiform: results of a meta-analysis. Oncol Res, 12: 107112, 2000.
22. Nishikawa R, Sugiyama T, Narita Y, Furnari F, Cavenee WK, Matsutani M: Immunohistochemical analysis of the mutant epidermal growth factor, delta EGFR, in glioblastoma. Brain Tumor Pathol, 21: 53-56, 2004.
23. Aldape KD, Ballman K, Furth A, Buckner JC, Giannini C, Burger PC, Scheithauer BW, Jenkins RB, James CD: Immunohistochemical detection of EGFRvIII in high malignancy grade astrocytomas and evaluation of prognostic significance. J Neuropathol Exp Neurol, 63: 700-707, 2004.
24. Stea B, Falsey R, Kislin K, Patel J, Glanzberg H, Carey S, Ambrad AA, Meuillet EJ, Martinez JD: Time and dose-dependent radiosensitization of the glioblastoma multiforme U251 cells by the EGF receptor tyrosine kinase inhibitor ZD1839 ('Iressa'). Cancer Lett, 202: 43-51, 2003.
25. Krishnan S, Rao RD, James CD, Sarkaria JN: Combination of epidermal growth factor targeted receptor therapy with radiation therapy for malignant gliomas. Front Biosci, 1: 11-13, 2003.
26. Chakravarti A, Seiferheld W, Tu X, Wang H, Zhang HZ, Ang KK, Hammond E, Curran W Jr, Mehta M: Immunohistochemically determined total epidermal growth factor receptor levels not of prognostic value in newly diagnosed glioblastoma multiforme: report from the Radiation Therapy Oncology Group. Int J Radiat Oncol Biol Phys, 62: 318-327, 2005.
27. Phuphanich S, Brat DJ, Olson JJ: Delivery systems and molecular targets of mechanism-based therapies for GBM. Expert Rev Neurother, 4: 649-663, 2004.
28. Isola JJ, Holli K, Teramoto Y, Kallioniemi OP: Elevated erbB-2 oncoprotein levels in preoperative and follow-up serum samples define in aggressive disease course in patients with breast cancer. Cancer, 73: 652-658, 1994.
29. Osaki T, Mitsudomi T, Nakanishi R, Yasumoto K: Serum level and tissue expression of c-erbB-2 in lung adenocarcinoma. Chest, 108: 157-162, 1995.
30. Carney WP, Neumann R, Lipton A, Leitzel K, Ali S, Price CP: Potential clinical utility of serum HER-2/neu oncoprotein concentrations in patients with breast cancer. Clin Chem, 49: 1579-1598, 2003.
31. Baron AT, Boardman CH, Lafky JN, Rademaker A, Liu D, Fishman DA, Podratz KC, Maihle NJ: Soluble epidermal growth factor receptor (sEGFR) [corrected] and cancer antigen 125 (CA 125) as screening and diagnostic tests for epithelial ovarian cancer. Cancer Epidemiol Biomarkers Prev, 14: 306-318, 2005.
32. Eichbaum MH, de Rossi TM, Kaul S, Bastert G: Serum levels of soluble E-selectin are associated with the clinical course of metastatic disease in patients with liver metastases from breast cancer. Oncol Res, 14: 603-610, 2004.